Development and Evaluation of Epitope-Blocking ELISA for Detection of Antibodies against Contagious Caprine Pleuropneumonia in Goat Sera

• Main Authors: Baziki Jean de Dieu, Bodjo S. Charles, Nick Nwankpa, Ethel Chitsungo, Cisse Rahamatou Moustapha Boukary, Naomi Maina, Takele A. Tefera, Rume Veronica Nwankpa, Nduta Mwangi, Yao Mathurin Koffi
• Format: Article
• Language: English
• Published: MDPI AG 2019-10-01
• Series: Veterinary Sciences
• Subjects: blocking-elisa; cut-off value; monoclonal antibody; sensitivity and specificity
• Online Access: https://www.mdpi.com/2306-7381/6/4/82

Enzyme linked immunosorbent assays (ELISAs) have been developed for the detection of antibodies against contagious caprine pleuropneumonia (CCPP), the causative agent of which is <i>Mycoplasma capricolum</i> subsp. <i>Capripneumoniae</i> (Mccp). The currently available commercial CCPP competitive ELISA (CCPP cELISA) kit produced and supplied by IDEXX Company (Westbrook, Maine, United States) is relatively expensive for most African laboratories. To address this issue and provide a variety of choices, a sensitive and specific blocking-ELISA (b-ELISA) test to detect antibodies against CCPP was developed. We describe the newly developed CCPP blocking-ELISA based on the blocking of an epitope of a monoclonal antibody (Mccp-25) by a positive serum sample against the Mccp protein coated on a plate. The Percentage Inhibition (PI) cut-off value for the CCPP b-ELISA was set at 50 using 466 CCPP negative and 84 CCPP positive small ruminant sera. Of the negative sera, 307 were obtained from the Botswana National Veterinary Laboratory (BNVL) and 159 from the Friedrich-Loeffler-Institute (FLI) Germany. The 84 positive sera samples came from experimentally vaccinated goats at the AU-PANVAC facility in Debre-Zeit, Ethiopia. The relative diagnostic sensitivity and specificity of the CCPP b-ELISA was 93% and 88%, respectively. This test result indicated good correlation with that of the commercial CCPP cELISA by IDEXX Company (Westbrook, Maine, United States) with a Cohen&#8217;s &#954; agreement of &#954; agreement of 0.85. The newly developed CCPP b-ELISA will be useful in the detection of antibodies for the diagnosis CCPP and for sero-surveillance during vaccination campaigns.